N/A N=666 Individualized Response to Vitamin D Treatment Study
Characteristics That Modify the Response to Cholecalciferol Treatment
Primary: Change in Serum 1,25(OH)2D Concentration — 2; -1 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
Phase 3 N=62 Improving the Understanding of the Response to Vitamin D Supplementation
Vitamin D Deficiency
Primary: Change in Serum 25-hydroxy Vitamin D3 — 6.0; -0.8; 10.4; 0.3 ng/ml
N/A N=81 Optimizing Vitamin D in the Elderly
Deficiency of Vitamin D3
Primary: Total 25-OH Vitamin D3 Level — 33; 34; 43; 61 ng/mL — p=<.0001
N/A N=47 Cholecalciferol Versus Doxercalciferol in the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
Renal Osteodystrophy
Primary: Percent Reduction in PTH — 27; 10 % change in PTH baseline to 3 months
N/A N=40 Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
Actinic Keratosis
Primary: Changes From Baseline in Actinic Keratosis - Lesion Base Count. — 1.15; 2.65; 1.15; 2.60 lesions — p=<0.001
N/A N=180 Magnesium Treatment on Vitamin D Metabolism in Participants Completed Personalized Prevention of Colorectal Cancer Trial
Colorectal Cancer
Primary: Comparisons of the Changes of Blood 25-Hydroxyvitamin D3 (25(OH)D3) Between Magnesium Treatment and Placebo Arm, Stratified by the Baseline 25-hydroxyvitamin D (25(OH)D)…
Phase 4 N=44 Vitamin D and Coronary Calcification Study
Chronic Kidney Disease · Vitamin D Deficiency · Coronary Calcification
Primary: Coronary Artery (CAC) Score Progression — 74.38; 106.32 Agatston units
N/A N=19 Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
N/A N=43 Vitamin D Supplementation to Obese Chinese Males
Obesity · Insulin Resistance
Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L
N/A N=34 Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects
Chronic Kidney Disease · Vitamin D Deficiency
Primary: 25-hydroxyvitamin D — 18.6; 17.3; 19.5; 49.4 ng/mL
N/A N=75 VItamin D Metabolism in SEnescent Cardiac Surgery Patients
Coronary Artery Bypass Grafting · Heart Valve Surgery
Primary: Peri- and Postoperative Time Course of Circulating 1,25-dihydroxyvitamin D in the First Postoperative Month in Cardiac Surgery Patients — 13; 4.2 percentage
N/A N=169 Personalized Vitamin D Supplementation in European and African Americans
Vitamin D Deficiency
Primary: Efficacy of the Dosing Algorithm in Achieving Total 25(OH)D as Measured by the Percentage of Participants Ending With Concentrations of 35-50 ng/mL — 61.3; 58.5; 47.6…
N/A N=68 Improving Vitamin D Status in Home-bound Elders
Vitamin D Deficiency · Accidental Falls
Primary: Change in 25-hydroxyvitamin D Levels Over 5 Months — 21.7; 0 ng/mL
Phase 4 N=19 Does Treatment of Hypovitaminosis D Increase Calcium Absorption?
Osteoporosis · Osteopenia · Vitamin D Deficiency
Primary: Change in Intestinal Calcium Absorption From Baseline to One Month — 3 percent calcium absorption
N/A N=20 Vitamin D Supplementation in Kidney Disease
Renal Dialysis · Vitamin D Deficiency
Primary: Change in Hip Flexor Strength — 20.34; 6.83 percent change
N/A N=30 Improving Vitamin D Status In Cystic Fibrosis
Cystic Fibrosis
Primary: 25-hydroxyvitamin D — 21.2; 24.4; 28.2 ng/mL
Phase 2 N=67 Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis
Severe Sepsis or Septic Shock
Primary: Plasma Cathelicidin (hCAP18) Protein Levels at 48 Hours — 76; 82 ng/ml — p=0.25
N/A N=37 Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients
Obesity · Vitamin D Deficiency
Primary: Vitamin D Concentrations, Pre Operative and Post Bariatric Surgery Following 12 Weeks of Vitamin D Supplementation — 19.1; 27.2 ng/mL — p=< 0.001
Phase 4 N=276 Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
End Stage Renal Disease
Primary: EPO Dose — 5800; 5400; 7000; 6050 units/week — p=0.78
Phase 4 N=230 Treatment of Vitamin D Insufficiency
Vitamin D Deficiency
Primary: Intestinal Calcium Absorption — 0.200; 0.217; 0.183; 0.206 Total Fractional Calcium Absorption
Phase 3 N=30 Cholecalciferol Supplementation for Sepsis in the ICU
Hypovitaminosis D
Primary: Change in Vitamin D Status 5 Days Following Supplementation With Cholecalciferol — 19; 15; 17; 19 ng/mL
Phase 2 N=550 Topical Delivery of Vitamin D3 as Vitamin D Supplementation
Vitamin D Deficiency
Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9
Phase 3 N=130 Vitamin D in Vulnerable Adults (VIVA-VA)
Frail Elderly · Vitamin d Deficiency
Primary: Change in Short Physical Performance Battery Test Score — 7.3; 7.0 units on a scale
Phase 3 N=1,358 Vitamin D to Improve Outcomes by Leveraging Early Treatment
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
N/A N=11 Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp
Vitamin D Deficiency · Short Bowel Syndrome
Primary: 25 Hydroxy Vitamin D Levels — 26; 14; 19; 17 ng/mL
Phase 2 N=22 Metabolic Effects of Paricalcitol
Chronic Kidney Disease
Primary: Glucose Area Under the Curve (AUC) — 20817; 21139 mg*min/dL
Phase 4 N=204 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder
Vitamin D Deficiency
Primary: The Blood Levels of Calcium at the 24th Month of Following up. — 2.31; 2.33 mmol/L — p=0.117
Phase 2 N=34 Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease
Anemia of Chronic Kidney Disease
Primary: Change in Serum Hepcidin With Vitamin D Intervention for Children With Chronic Kidney Disease — 48.2; 75.4 ng/ml
Phase 2 N=25 Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48